Skip to main content
. 2021 Dec 7;9(12):1857. doi: 10.3390/biomedicines9121857

Figure 1.

Figure 1

Thalidomide ameliorates skin inflammation by decreasing CD8+ T cells, increasing iNK-Tcells and promoting a Th2 response in CLE. (a) Flow cytometry percentages of T helper (CD3+CD4+), T cytotoxic cells (CD3+CD8+) and iNK Tcells (CD3+6B11+) in PBMCs of responder patients (n = 7) before and after thalidomide treatment. (b) Post-thalidomide, CLE patients had lower percentages of Th1 (CCR5+ CXCR3+) T cells and higher percentages of Th2 (CCR4+CCR3+). (c) Skin immunohistochemistry to evaluate infiltrating CD4+ and CD8+ in skin biopsies of CLE. Graphs represent the average signal intensity (n = 3). (d) Immunofluorescence of post-treatment skin samples showed a significant increase of iNK Tcells (6B11+ cells). Scale bar = 200mm. * p < 0.05; ** p < 0.005; *** p < 0.0001.